How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Autism Spectrum Disorder (ASD) Market
- By Product Type: Diagnostic and Monitoring Devices, Therapeutic and Rehabilitation Devices, Behavioral Assessment Tools, Educational Software and Applications, Pharmaceuticals
- By Treatment Type: Behavioral Therapy, Pharmacological Therapy, Speech Therapy, Occupational Therapy, Physical Therapy
- By End User: Hospitals and Clinics, Specialized Autism Centers, Home Care Settings, Educational Institutions, Research and Academic Institutes
- By Age Group: Children (0-12 years), Adolescents (13-17 years), Adults (18+ years)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Diagnostic and Monitoring Devices leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.167 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.175 →
Full report · locked preview
Everything inside the Autism Spectrum Disorder (ASD) Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
By Product Type 5
By Treatment Type 5
By End User 5
By Age Group 3
Companies profiled
Roche
Novartis
Johnson & Johnson
Pfizer
Eli Lilly and Company
Otsuka Pharmaceutical
Takeda Pharmaceutical
Sunovion Pharmaceuticals
Neurocrine Biosciences
Acadia Pharmaceuticals
Lundbeck
H. Lundbeck A/S
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Novartis
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pfizer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Otsuka Pharmaceutical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Takeda Pharmaceutical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sunovion Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Neurocrine Biosciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Acadia Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Lundbeck
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →H. Lundbeck A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Biogen
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Medice Arzneimittel Pütter GmbH & Co. KG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Seaside Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,468M by 2033 · 9.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Diagnostic and Monitoring Devices51.7
- Therapeutic and Rehabilitation Devices9.4
- Behavioral Assessment Tools13.6
- Educational Software and Applications17.1
- Pharmaceuticals8.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$868.2M → $1,743M · 9.1%
Europe$605.1M → $1,396M · 11.0%
Asia Pacific$552.5M → $1,131M · 9.4%
Latin America$342.0M → $724.5M · 9.8%
Middle East and Africa$263.1M → $569.6M · 10.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.522026
9.542027
9.562028
9.562029
9.582030
9.582031
9.592032
9.622033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche19.2
- Novartis26.0
- Johnson & Johnson5.1
- Pfizer9.9
- Eli Lilly and Company5.5
- Otsuka Pharmaceutical6.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →By Product Type18.1%
By Treatment Type25.4%
By End User34.2%
By Age Group22.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.3
- Europe25.1
- Asia Pacific20.3
- Latin America13.0
- Middle East and Africa10.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche | 96 | 81 | 83 | 78 | 97 | 87 | 87 |
| Novartis | 68 | 75 | 76 | 79 | 75 | 91 | 77 |
| Johnson & Johnson | 82 | 75 | 86 | 84 | 81 | 67 | 79 |
| Pfizer | 74 | 63 | 70 | 68 | 80 | 72 | 71 |
| Eli Lilly and Company | 73 | 60 | 62 | 63 | 62 | 61 | 64 |
| Otsuka Pharmaceutical | 46 | 57 | 65 | 65 | 54 | 65 | 59 |
| Takeda Pharmaceutical | 51 | 53 | 61 | 42 | 44 | 56 | 51 |
| Sunovion Pharmaceuticals | 57 | 45 | 56 | 38 | 37 | 51 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche
- Novartis
- Johnson & Johnson
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Novartis | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Johnson & Johnson | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Pfizer | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Eli Lilly and Company | ✓ | ◐ | − | ◐ | − | ✓ |
| Otsuka Pharmaceutical | ◐ | − | ◐ | ◐ | ◐ | ✓ |
| Takeda Pharmaceutical | − | − | ◐ | − | − | ◐ |
| Sunovion Pharmaceuticals | − | ◐ | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche87
2Johnson & Johnson79
3Novartis77
4Pfizer71
5Eli Lilly and Company64
6Otsuka Pharmaceutical59
7Takeda Pharmaceutical51
8Sunovion Pharmaceuticals47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
RocheJohnson & Johnson
Challenger2
Strong scale, closing on the leaders.
NovartisPfizer
Contender2
Focused players with pockets of strength.
Eli Lilly and CompanyOtsuka Pharmaceutical
Niche2
Specialists in a single segment or region.
Takeda PharmaceuticalSunovion Pharmaceuticals
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land By Product Type in North America, then scale across Autism Spectrum Disorder (ASD) Market — a $63M beachhead inside a $859M market.
Beachhead (SOM)$63Mobtainable near-term
Serviceable (SAM)$342Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Diagnostic and Monitoring Devices
Best fit — highest urgency & budget in By Product Type.
Economic buyer79 fit
Therapeutic and Rehabilitation Devices
Strong fit — clear ROI and a fast path to value.
End user70 fit
Behavioral Assessment Tools
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win By Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add By Treatment Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + By End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve19%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For By Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Autism Spectrum Disorder (ASD) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified23%
Evaluation13%
Closed-won6%
$18.3KCAC
$86KLTV
4.7:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Autism Spectrum Disorder (ASD) Market is a durable-growth opportunity — $1.12B by 2033, compounding at 8.9%.
TAM · 2025$566Mtoday
TAM · 2033$1.12Bforecast
CAGR8.9%2027–2033
Cumulative$7.35Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.12BTotal addressable market
SAM$394MServiceable available market
SOM$71MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.9% CAGR
Demand compounds through 2033, outpacing GDP across By Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in By Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.12BLarge & growingTAM by 2033 at 8.9% CAGR
$394MServiceable nowreachable with today’s model
$71MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$875MBear5.8% CAGR
$1.12BBase8.9% CAGR
$1.44BBull11.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & By Treatment Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Autism Spectrum Disorder (ASD) Market — a $1.13B market by 2033. Plan: grow share from 7.6% to 16.0%.
Market size · 2033$1.13Btotal addressable
Market CAGR8.4%2027–2033
Target share16.0%from 7.6% today
Revenue ambition$181Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.6% | 16.0% | On track |
| Revenue | $83M | $181M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 32.2% | 39.0% | On track |
| Customer retention | 85.3% | 94.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in By Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build By Treatment Type capability
A defensible second engine — invest in By Treatment Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core By Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch By Treatment Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $20M capacity & capability investment
- Greenlight bolt-on M&A in By Treatment Type
- Authorise North America expansion plan
- Fund R&D program for By Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Autism Spectrum Disorder (ASD) Market conversation — a $9.59B market you can size, segment and defend in minutes.
Market size · 2033$9.59Btotal opportunity
Growth7.1%CAGR to 2033
Addressable buyers1,580+accounts in scope
Typical ROI4.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of By Product Type
Goal Grow share in By Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.4×return on cost, year one
< 3 mopayback period
$74K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
RocheNovartisJohnson & JohnsonPfizerEli Lilly and CompanyOtsuka PharmaceuticalTakeda PharmaceuticalSunovion Pharmaceuticals+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Autism Spectrum Disorder (ASD) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Autism Spectrum Disorder (ASD) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Autism Spectrum Disorder Management Market
Market size, share, segmentation and regional forecast.
$777M market · 2025 base year
View reportAutism Spectrum Disorder Therapeutics Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportAuto Abs Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportAuto Adjusting CPAP Machines Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportAuto Bag Drop (ABD) Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportAuto Batteries Market
Market size, share, segmentation and regional forecast.
$454M market · 2025 base year
View reportAuto Bearing Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportAuto Brake Systems Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportAuto Cable Reel Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportAuto Claim Management Software Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportAuto Classifieds Market
Market size, share, segmentation and regional forecast.
$870M market · 2025 base year
View reportAuto Climb Systems for Wind Turbine Towers Market
Market size, share, segmentation and regional forecast.
$385M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.